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35 months, which equates to roughly one opportunity 
per ward per week. Yet, the care of one patient in 
intensive care creates more than 150 hand hygiene 
opportunities per day,13 emphasising the fact that 
direct human observation can only measure a trivial 
proportion of the hand hygiene events that occur.11 
The fact that human observers are able to monitor 
less than 0·1% of hand hygiene opportunities is only a 
problem if hand hygiene performance systematically 
diﬀ ers between observed and unobserved periods. 
Unfortunately, in trials using electronic monitoring 
systems to track all hand hygiene events on one or 
more wards,11,12 the number of hand hygiene events 
increased by three to four times when a human observer 
was present. Therefore, observed and unobserved 
hand hygiene compliance seem to be totally separate 
phenomena. If the only reason a health-care worker 
performs hand hygiene half the time is because they are 
being observed, the eﬀ ect of any intervention aimed at 
changing behaviour will be muted, thus biasing studies 
towards the null hypothesis if they rely on measurement 
of observed hand hygiene compliance.
At present, various electronic hand hygiene moni-
toring systems exist and more are in development.14 As 
we move from retrospective before-and-after studies 
to complex, multicentre cluster randomised controlled 
trials, we should also abandon direct human observation 
and adopt an objective and reproducible outcome 
measure of hand hygiene performance.
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More pieces to the microcephaly–Zika virus puzzle in Brazil
By October, 2015, the Zika virus epidemic had grown 
substantially in Brazil with 14 states reporting auto-
chtho nous Zika virus transmission. Concurrently, 
con cerns were raised regarding the discovery of a sub-
stantial increase in the number of microcephaly cases, 
particularly in the state of Pernambuco. The follow-
ing month, a national public health emergency was 
declared in Brazil in response to growing concerns 
about the potential association between Zika virus 
and newborn microcephaly, with 1248 reported 
cases—20 times greater than the expected number.1 
Following this announce ment, additional progress 
was made in establishing more deﬁ nitive associations 
between Zika virus and congenital anomalies, including 
microcephaly.2,3
Studies in mouse models have addressed the causal 
relation between Zika virus infection in pregnancy 
and pathological changes in fetuses.4,5 Although a 
growing body of evidence suggests that Zika virus 
causes brain anomalies and microcephaly, describing 
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what has been identiﬁ ed as congenital Zika virus 
infec tion syndrome, there is a paucity of published 
prospective epidemiological studies.3 A study by Thalia 
Araújo and colleagues6 in The Lancet Infectious Diseases 
might be a missing piece to the puzzle, providing 
necessary epidemiological data to further advance our 
understanding of the association.
The investigators report preliminary ﬁ ndings from 
the ﬁ rst case-control study to examine the association 
between microcephaly and Zika virus infection, done 
prospectively in the metropolitan region of Recife in 
Pernambuco state, the hotspot of the microcephaly 
epidemic in Brazil. Their results highlight the striking 
magnitude of the association between microcephaly 
and laboratory-conﬁ rmed Zika virus infection: the risk 
is 50 times higher in all microcephaly cases and more 
than 100 times higher in cases with brain abnormalities 
detected by imaging.
However, as acknowledged by Araújo and colleagues, 
microcephaly remains a poorly deﬁ ned disorder, and 
a uniform diagnostic approach is urgently needed. 
There is much debate in Brazil and worldwide about 
ascertainment of microcephaly, and the issue of dis-
proportionate and proportionate microcephaly needs 
further clariﬁ cation. Infants might be diagnosed 
with microcephaly when in fact they are globally 
small—ie, small for gestational age, without true 
isolated microcephaly.7 This issue deserves attention, 
especially because in-utero growth restriction leading 
to the birth of small-for-gestational age infants is 
also a feature of congenital Zika virus syndrome.2 
Although disproportionate microcephaly has been 
the most publicised feature of congenital Zika virus 
infection, proportionate microcephaly is also identiﬁ ed 
in the setting of in-utero growth restriction caused 
by maternal Zika virus infection during pregnancy, 
not unlike other congenital infections such as cyto-
mega lovirus. The distinction, however, is important 
because there might be distinct prognostic implications. 
Although microcephaly has been associated with poor 
outcome in children with congenital cytomegalovirus 
disease, other researchers have not found such an 
association. A possible source of discrepancy is failure 
to adjust the head size to the weight of the infant when 
deﬁ ning microcephaly.8
Therefore, proportionality or lack thereof is becoming 
a very important parameter in ascertainment of 
microcephaly in Brazil. Likewise, categorising patients 
according to the presence of microcephaly and other 
CNS abnormalities as detected by brain imaging can 
enable the stratiﬁ cation of patients into varying levels of 
disability risk.
As our knowledge of the clinical repercussions of 
congenital Zika virus infection advances, it becomes 
apparent that microcephaly is only one possible adverse 
outcome among a range of disorders that might be 
part of congenital Zika virus syndrome. A population-
level increase in CNS anomalies was observed in French 
Polynesia and in Brazil. More data are needed to reﬁ ne 
gestational age-speciﬁ c risk estimates for microcephaly 
and other adverse outcomes related to Zika virus 
infection.9 Therefore, even though the modiﬁ ed 
Fenton curve10 or the Intergrowth score11 provide useful 
prognostic information, a full clinical assessment of 
the infant with clinical follow-up should provide more 
accurate information over time.
As deﬁ nitions shift and more information is gathered 
about the pathogenesis and clinical manifestations 
of Zika virus congenital disease, it is important that 
surveillance eﬀ orts monitoring the current epidemic 
continue to critically evaluate their data. Newly 
identiﬁ ed clinical and phenotypic criteria should be 
further analysed, also taking into account ﬁ ndings from 
imaging studies. This approach will help establish a more 
deﬁ nitive gold standard case deﬁ nition and improve 
our understanding of the clinical manifestations of 
congenital Zika virus infection.
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MRSA community pneumonia: a global perspective on 
resistance
In The Lancet Infectious Diseases, Stefano Aliberti and 
colleagues1 showed remarkable variation in the prevalence 
of Staphylococcus aureus and meticillin-resistant S aureus 
(MRSA) among pathogens causing com munity-acquired 
pneumonia in 54 countries on six continents in 2015. 
Worldwide, they found 95 patients tested positive 
for MRSA, meaning the resistant strain caused 8% of 
community-acquired pneumonia infections among adult 
patients with a pathogen identiﬁ ed (culture-positive 
cohort; n=1173) and 3% of infections in those who had 
one or more microbiological test done (n=3193). 
The epidemiology of MRSA shifted after 1995 with 
the emergence worldwide of a number of community-
associated MRSA strains. Nearly all of these strains carry 
the phage-encoded Panton-Valentine leukocidin (PVL) 
and staphylococcal cassette chromosome mec (SCCmec) 
type IV or V.2 Some researchers have linked PVL to severe 
necrotising pneumonia.3–6 However, there is controversy 
about the role of PVL in the pathogenesis of pneumonia.7 
SCCmec is a mobile genetic element that carries the 
mecA gene, which bestows meticillin resistance upon 
an S aureus strain. For reasons that remain unknown, 
community-associated MRSA strain types globally 
diﬀ er in geographic distribution and in prevalence. The 
predominant strains are USA300 (ST8) in North America, 
ST80 in Europe, ST93 in Australia, and ST59 in east Asia.2 
Aliberti and colleagues found that Oceania (30·8%), 
South America (29·2%) and North America (26·4%) 
were the continents with the highest prevalence of 
S aureus among patients with culture-positive com-
munity-acquired pneumonia. What accounts for the wide 
variability by continent in this prevalence (12·6–30·8%) 
is not known. The prevalence of MRSA in this cohort 
(range 6·1–16·4%) was highest in North America (16·4%), 
South America (15·3%), and Oceania (7·7%), perhaps due 
to the more virulent or ﬁ t nature of locally circulating 
community associated MRSA strain types or perhaps due 
to a higher prevalence of colonisation in the population 
of these continents. Among patients in North America 
with community-acquired pneumonia who had at least 
one diagnostic test for a pathogen, Aliberti and colleagues 
found that 4·8% had MRSA. This was substantially higher 
than the prevalence found by researchers in a ﬁ ve-hospital 
US study in 2010–12, in which the prevalence was only 
0·7%.8 The reason for this diﬀ erence could be geographic 
variability within North America. 
Aliberti and colleagues compared the 95 patients with 
community-acquired pneumonia caused by MRSA with 
the other 3098 patients who were tested for a bacterial 
aetiology but in whom MRSA was not identiﬁ ed. 
Assessing 64 putative predictor variables, the authors 
found that MRSA pneumonia was independently 
associated only with three: previous MRSA infections 
or colonisation, a history of recurrent skin infections, 
and severe pneumonia disease. The ﬁ rst two risk factors 
suggest that recurrent staphylococcal infections might 
be a distinguishing factor for MRSA pneumonia. Few 
authors have studied recurrent clinically signiﬁ cant 
MRSA infections when initial and subsequent infections 
are at diﬀ erent anatomic sites. The study of only same-
tissue or same-organ system recurrences might obscure 
the association between a relatively minor MRSA skin 
infection preceding an invasive infection. In future 
longitudinal studies, whole-genome sequencing could 
be used to determine whether invasive infections and 
prior skin infections were caused by a single clone of 
MRSA, as is commonly assumed. Such studies might 
enable us more eﬃ  ciently to implement preventative 
measures, such as a decolonisation regimen, in targeted 
popu lations to prevent invasive infections. 
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